Afortiori Bio

Afortiori Bio is a preclinical biotechnology company developing RNA medicines for chronic liver disease, particularly liver fibrosis.

Its lead programme uses Target Site Blocker RNA technology to selectively modulate gene expression in liver cells. The approach is intended to address processes contributing to fibrotic scarring and progression towards cirrhosis.

The company is advancing preclinical research; its ability to halt or reverse liver fibrosis has not been demonstrated in patients.